FAVARETTO, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 134
AS - Asia 90
EU - Europa 66
SA - Sud America 15
AF - Africa 7
Totale 312
Nazione #
US - Stati Uniti d'America 134
CN - Cina 45
SG - Singapore 25
IE - Irlanda 17
DE - Germania 14
RU - Federazione Russa 12
BR - Brasile 11
HK - Hong Kong 7
IT - Italia 7
VN - Vietnam 5
FR - Francia 4
ZA - Sudafrica 4
IN - India 3
BE - Belgio 2
CO - Colombia 2
FI - Finlandia 2
UY - Uruguay 2
AT - Austria 1
CZ - Repubblica Ceca 1
EE - Estonia 1
EG - Egitto 1
GB - Regno Unito 1
HU - Ungheria 1
IQ - Iraq 1
JO - Giordania 1
KE - Kenya 1
LT - Lituania 1
MA - Marocco 1
PK - Pakistan 1
PL - Polonia 1
SA - Arabia Saudita 1
TR - Turchia 1
UA - Ucraina 1
Totale 312
Città #
Dallas 21
Chandler 19
Dublin 17
San Jose 17
Singapore 17
Ashburn 14
Beijing 11
Nanjing 8
Hong Kong 7
Munich 7
New York 7
Ann Arbor 6
São Paulo 5
Boardman 4
Johannesburg 4
Moscow 4
Frankfurt am Main 3
Hanoi 3
Hebei 3
Jiaxing 3
Milan 3
Shanghai 3
Brussels 2
Changsha 2
Düsseldorf 2
Lauterbourg 2
Lawrence 2
Los Angeles 2
Medford 2
Montevideo 2
Nanchang 2
Norwalk 2
Princeton 2
Redondo Beach 2
Turin 2
Amman 1
Ankara 1
Brno 1
Buffalo 1
Bến Tre 1
Cairo 1
Campo Mourão 1
Changzhou 1
Chennai 1
Chicago 1
Columbus 1
Denver 1
Fairfield 1
Foshan 1
Gujranwala 1
Helsinki 1
Indaial 1
Jeddah 1
Jinan 1
Kyiv 1
London 1
Medellín 1
Mosul 1
Nairobi 1
New Delhi 1
Passo Fundo 1
Piscataway 1
Rabat 1
Santa Bárbara d'Oeste 1
Santa Clara 1
Santa Maria 1
Seattle 1
Shijiazhuang 1
Srinagar 1
Suffern 1
São Francisco de Paula 1
Tallinn 1
Thanh Hóa 1
Turku 1
Vienna 1
Warsaw 1
Washington 1
Waterbury 1
Wuhan 1
Yarumal 1
Totale 257
Nome #
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 135
Advanced non-small cell lung cancer management in patients progression after first-line treatment: results of the cross-sectional phase of the Italiane LIFE OBSERVATIONAL STUDY 106
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial 74
Totale 315
Categoria #
all - tutte 1.303
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.303


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 0 1
2021/202215 0 0 1 0 0 2 0 2 2 0 1 7
2022/202350 2 4 1 5 1 8 0 4 24 1 0 0
2023/202429 2 1 1 2 0 7 0 4 0 1 1 10
2024/202560 2 3 1 1 2 4 1 5 15 3 5 18
2025/2026133 11 12 24 12 18 4 25 8 12 7 0 0
Totale 315